Zura Bio Limited (NASDAQ:ZURA) EVP Kiran Nistala Buys 3,195 Shares

Zura Bio Limited (NASDAQ:ZURA) EVP Kiran Nistala purchased 3,195 shares of the company’s stock in a transaction that occurred on Monday, April 22nd. The stock was bought at an average price of $3.13 per share, with a total value of $10,000.35. Following the purchase, the executive vice president now owns 3,195 shares of the company’s stock, valued at approximately $10,000.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Zura Bio Stock Down 4.9 %

ZURA stock traded down $0.17 during trading on Wednesday, hitting $3.31. 826,726 shares of the company’s stock traded hands, compared to its average volume of 278,140. Zura Bio Limited has a 52 week low of $2.00 and a 52 week high of $14.00. The stock has a fifty day moving average price of $3.21 and a two-hundred day moving average price of $4.04.

Analyst Ratings Changes

Separately, Oppenheimer restated an “outperform” rating and issued a $16.00 price target (down previously from $17.00) on shares of Zura Bio in a research note on Monday, April 1st. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $16.40.

Institutional Trading of Zura Bio

Several institutional investors have recently added to or reduced their stakes in the business. Forefront Analytics LLC increased its stake in Zura Bio by 46.8% during the fourth quarter. Forefront Analytics LLC now owns 21,229 shares of the company’s stock valued at $99,000 after purchasing an additional 6,765 shares during the last quarter. Armistice Capital LLC grew its position in shares of Zura Bio by 15.4% during the fourth quarter. Armistice Capital LLC now owns 1,824,000 shares of the company’s stock worth $8,518,000 after acquiring an additional 244,000 shares during the last quarter. Lynx1 Capital Management LP bought a new position in shares of Zura Bio during the third quarter worth about $65,000. Eisler Capital US LLC bought a new position in shares of Zura Bio during the third quarter worth about $660,000. Finally, Silverarc Capital Management LLC grew its position in shares of Zura Bio by 152.5% during the third quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company’s stock worth $2,667,000 after acquiring an additional 244,040 shares during the last quarter. Institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.